CARGO Therapeutics

curocell

This company develops chimeric antigen receptor T-cell therapies to treat patients with relapsed or refractory blood cancers such as diffuse large B-cell lymphoma.

Verismo Therapeutics

This company develops chimeric antigen receptor therapies for patients with solid tumours and B-cell lymphomas.

Neogene Therapeutics

This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.

March Biosciences

This clinical-stage company develops CAR-T cell therapies for patients with challenging hematological cancers, including T-cell lymphoma.

Arcellx

This biotechnology company develops cell therapies to treat patients with cancer and autoimmune diseases.

Tango Therapeutics

This biotechnology company develops precision oncology medicines targeting genetic vulnerabilities in cancer cells for patients with solid tumours.

Caribou Biosciences

This biopharmaceutical company develops genome-edited allogeneic cell therapies to treat patients with hematologic malignancies and other human diseases.

Profound Bio

This clinical-stage biotechnology company develops antibody-drug conjugates and targeted therapies for patients with solid tumors and hematological malignancies.